Premium
OS Therapies Incorporated (OSTX)
AMEX
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a...
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief...
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to...
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.6 | 84.2105263158 | 1.9 | 4.77 | 1.8914 | 198205 | 3.48643008 | CS |
| 4 | 1.3 | 59.0909090909 | 2.2 | 4.77 | 1.58 | 73909 | 3.02710553 | CS |
| 12 | -0.01 | -0.2849002849 | 3.51 | 4.77 | 1.58 | 44602 | 2.96675754 | CS |
| 26 | -0.5 | -12.5 | 4 | 4.9 | 1.58 | 125802 | 3.63536424 | CS |
| 52 | -0.5 | -12.5 | 4 | 4.9 | 1.58 | 125802 | 3.63536424 | CS |
| 156 | -0.5 | -12.5 | 4 | 4.9 | 1.58 | 125802 | 3.63536424 | CS |
| 260 | -0.5 | -12.5 | 4 | 4.9 | 1.58 | 125802 | 3.63536424 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
